Gates Foundation Strategic Investment Fund Logo
Share this page:

Global Health Advisors

Bruce Booth

Partner at Atlas Venture

Bruce Booth focuses on novel biopharmaceutical products, therapeutic platforms, and innovative biomedical technologies. Bruce is currently chairman of AvroBio (NASDAQ:AVRO), Kymera Therapeutics, Hotspot Therapeutics, miRagen Therapeutics (NASDAQ:MGEN), Nimbus Therapeutics, Rodin Therapeutics, and Unum Therapeutics (NASDAQ:UMRX), and also serves on the boards of Lysosomal Therapeutics, and Magenta Therapeutics (NASDAQ:MGTA). He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Padlock (acquired by BMS), Prestwick (acquired by Biovail), Stromedix (acquired by Biogen), Zafgen (NASDAQ:ZFGN), and a number of other ventures.

Bruce serves as an advisor in various capacities to UCB, Takeda, and the Gates Foundation. He also serves on the board of the National Venture Capital Association.

Bruce blogs about biotech and venture capital topics at LifeSciVC.com, which is syndicated on Forbes. He has published numerous scientific papers and has authored various biotech venture capital review articles, including several in Nature Biotechnology.

Prior to joining Atlas in 2005, Bruce was a consultant at McKinsey & Company, as well as an investor for Caxton Health Holdings. As a British Marshall Scholar, Bruce received a D.Phil. (PhD) in molecular immunology from Oxford University. His work focused on the study of HIV and tumor immune responses. He received a BS in biochemistry, summa cum laude, from The Pennsylvania State University.

 

Kim Kamdar, Ph.D.

Partner at Domain Associates

Dr. Kamdar is a Partner at Domain Associates, Kim has been involved in cutting-edge therapeutic start-ups and has been a major part of identifying companies with promising molecular and companion diagnostics to support personalized medicine.

Present board memberships include Aspen Neuroscience, Epic Sciences, Evofem Biosciences, Obalon Therapeutics, Omniome, ROX Medical, Sera Prognostics, Truvian Sciences, and Singular Genomics. Formerly, Kim was a Kauffman Fellow with MPM Capital. Prior to joining MPM she was a research director at Novartis, where she built and led a research team that focused on the biology, genetics and genomics of model organisms. Kim is the author of ten papers as well as the inventor on seven patents. She received her B.A. from Northwestern University and her Ph.D. in biochemistry and genetics from

Emory University. Kim serves as an advisory board member of Dr. Eric Topol’s NIH supported Clinical and Translational Science Award for Scripps Medicine.

 

Bob More

Managing Director of Alta Partners

Previously, Bob was a Senior Advisor for the Bill and Melinda Gates Foundation and remains an advisor to the foundation. Prior to that, Bob spent 5 years as a General Partner at Frazier Healthcare Ventures and 13 years at Domain Associates. Bob  has managed investments in the healthcare industry and served on the boards of biotech, medical device and healthcare technology companies.

He was a founding Board member of the Kauffman Fellows Program and One Revolution and currently serves on the board of BIO (Biotechnology Innovation Organization).

He received his B.A. from Middlebury College and an M.B.A. from the Darden School of Business Administration at the University of Virginia.

 

Jenny Rooke, PhD

Founder, Managing Director at Genoa Ventures

For over a decade, Genoa Ventures’ founder and managing director Dr. Jenny Rooke has been deploying capital at the frontiers of life sciences innovation, with a penchant for technology-fueled solutions and category-defying opportunities. Jenny got her start in venture at Fidelity Biosciences, a Cambridge-based healthcare VC, during their Fund I formation. Jenny then brought her unique toolkit of genetics domain expertise, strategic business acumen, and venture investing to the Gates Foundation, where she deployed and managed over $250M in funding in genetic engineering, diagnostics, and synthetic biology. She also played a key role in establishing the foundation’s investing function.

In 2014, Dr. Rooke began independently investing under the brand 5 Prime Ventures, financing her investments using what has become the largest life sciences syndicate on AngelList, and one of the highest-performing AngelList syndicates of any sector. Jenny founded Genoa Ventures in 2018, building on the 5 Prime Ventures track record, in order to scale a proven, differentiated investing strategy, to ensure continued access to the very best deals, and to maximize portfolio returns.

 

Krishna Yeshwant

General Partner at Google Ventures

Dr. Krishna Yeshwant is a physician, programmer, and entrepreneur who has been working with GV since its inception. He first joined Google as part of the New Business Development team.

Prior to Google, Krishna helped start an electronic data interchange company that was acquired by Hewlett-Packard and a network security company that was acquired by Symantec.

Krishna has a B.S. in computer science from Stanford University. He also earned an M.D. from Harvard Medical School, an MBA from Harvard Business School, and completed his residency at Brigham and Women’s Hospital in Boston, Massachusetts where he continues to practice.